Regeneron Pharmaceuticals, Inc. (REGN) is Lagoda Investment Management L.P.’s 2nd Largest Position
Lagoda Investment Management L.P. increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,717 shares of the biopharmaceutical company’s stock after purchasing an additional 1,285 shares during the period. Regeneron Pharmaceuticals makes up 9.0% of Lagoda Investment Management L.P.’s portfolio, making the stock its 2nd biggest position. Lagoda Investment Management L.P. owned about 0.05% of Regeneron Pharmaceuticals worth $24,912,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of REGN. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $130,000. Sterling Investment Advisors Ltd. grew its stake in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the last quarter. FNY Partners Fund LP grew its stake in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares during the last quarter. IFP Advisors Inc grew its stake in Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 96 shares during the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $206,000. 66.67% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. Company insiders own 10.80% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $373.61 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The firm has a market cap of $40,303.59, a price-to-earnings ratio of 32.48, a price-to-earnings-growth ratio of 1.47 and a beta of 1.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same period last year, the business posted $3.13 earnings per share. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current year.
REGN has been the topic of several research analyst reports. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group reissued a “hold” rating and set a $500.00 price target (up from $471.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, September 29th. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 31st. Finally, Evercore ISI decreased their price target on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research note on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $467.84.
TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) is Lagoda Investment Management L.P.’s 2nd Largest Position” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-is-lagoda-investment-management-l-p-s-2nd-largest-position/1751171.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.